Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06272487 · ClinicalTrials.gov registry record · Phase 2
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 375
- Enrollment target
NCT06272487 is a Phase 2 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 375 participants.
The verdict
NCT06272487, a Phase 2 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 375 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Interventions
- DRUG Placebo
- DRUG Zilebesiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2024-02-29 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06272487
The ClinicalTrials.gov registry entry for NCT06272487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06272487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06272487 about?
NCT06272487 is a clinical study titled "Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)". The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
What is the current status of trial NCT06272487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 375 participants. The study started on 2024-02-29. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT06272487?
The interventions under investigation include: Placebo (DRUG), Zilebesiran (DRUG).
Who is sponsoring clinical trial NCT06272487?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.